Lilly to launch pragmatic study of Covid-19 drug candidate bamlanivimab in New Mexico
Eli Lilly and Company (Lilly) has revealed plans to launch a new pragmatic study of bamlanivimab (LY-CoV555) in high-risk patients with Covid-19, in partnership with ... Read More
Bamlanivimab Covid-19 drug candidate : Lilly, UnitedHealth Group join forces for pragmatic study
Eli Lilly and Company (Lilly) has entered into a partnership with managed care company UnitedHealth Group to carry out a pragmatic study of bamlanivimab (LY-CoV555) ... Read More
Lilly’s Covid-19 candidate bamlanivimab gets FDA’s EUA
The US Food and Drug Administration (FDA) has issued emergency use authorization (EUA) for bamlanivimab (LY-CoV555) 700 mg, the investigational neutralizing antibody of Eli Lilly ... Read More
Lilly signs $375m deal to supply Covid-19 candidate bamlanivimab to US govt
Eli Lilly and Company (Lilly) has signed a $375 million deal with the US government for the supply of 300,000 vials of bamlanivimab (LY-CoV555) 700mg, ... Read More
Lilly, Amgen collaborate to boost supply of potential COVID-19 therapies
Eli Lilly and Company has entered into a global antibody manufacturing collaboration with Amgen to considerably boost the supply capacity for its potential COVID-19 therapies. ... Read More
Lilly begins phase 1 coronavirus antibody trial with LY-CoV555
Coronavirus antibody trial : US pharma giant Eli Lilly and Company (Lilly) said that patients have been dosed in a phase 1 clinical trial with ... Read More